Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032

Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032

The global antisense and RNAi therapeutics market size is expected to reach USD 18.43 billion by 2032, according to a new study by Polaris Market Research. The report “Antisense and RNAi Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Technology (Antisense RNA and RNA Interference); By Route of Administration; By Application; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The global market for antisense and RNAi therapeutics has seen significant growth due to advancements in RNA-based drug development and improved understanding of disease mechanisms. These technologies are now being explored for new indications beyond their current uses, with many pipeline drugs targeting conditions with limited treatment options. Neurodegenerative disorders, such as Alzheimer's and Huntington's, are particularly challenging to treat, but emerging research suggests that RNA interference could offer new possibilities for addressing these conditions.

The expanding trend of multidisciplinary development approaches is having a substantial impact on the global market for antisense and RNAi therapies. Traditionally, preclinical and clinical research, regulatory affairs, and discovery were all conducted in distinct silos during the drug development process. Currently, nevertheless, there is a movement toward more integrated, interdisciplinary models that combine several fields of knowledge throughout the whole drug development life cycle.

RNAi and antisense medicines, which pose special technical obstacles, are benefiting from this comprehensive, cooperative approach. These nucleic acid-based medications necessitate input from a broad range of scientific disciplines, including molecular biology, biochemistry, pharmacology, and clinical medicine, due to their very mechanism of action. These specialist skill sets can work in multidisciplinary teams to progress antisense and RNAi candidates more efficiently as a group.

Untapped emerging markets offer significant growth opportunities for the global antisense and RNAi therapeutics market. Many developing countries have large numbers of patients suffering from life-threatening diseases, but they face limited or unavailable treatment options due to poor healthcare infrastructure and lack of access. Antisense and RNAi therapeutics have the potential to greatly improve patient outcomes in these countries by providing targeted treatments that are cost-effective and have fewer side effects than traditional drugs. This could expand access to essential medicines and facilitate the development of affordable new therapies for major diseases such as cancer, cardiovascular diseases, and hepatitis C, which have high mortality rates in these regions. Addressing the substantial unmet medical needs of underserved populations in these regions could be a driving force for market growth.

Antisense and RNAi Therapeutics Market Report Highlights

The antisense RNA segment dominated the market in 2023, driven by conducting tests on it to regulate various conditions.

The intrathecal injections segment led the market in 2023 and is expected to maintain its dominance due to its application in pain management and introduction of medications to fight particular infections.

North America holds a significant revenue share in the global antisense and RNAi therapeutics market, driven by major biopharmaceutical companies and heavy investment made by them in activities such as research and development.

The global key market players include Alynylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma, Inc., GSK plc, Ionois Pharmaceuticals, Inc., Olix Pharmaceuticals, and Sanofi.

Polaris Market Research has segmented the Antisense and RNAi therapeutics market report based on technology, route of administration, application, and region:

Antisense and RNAi therapeutics, Technology Outlook (Revenue - USD Billion, 2019 - 2032)

Antisense RNA

RNA Interference

Others

Antisense and RNAi therapeutics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Intrathecal Injections

Subcutaneous Injections

Intravenous Injections

Other Delivery Methods

Antisense and RNAi therapeutics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Neurodegenerative Disorders

Genetic Disease

Cancer

Cardiometabolic & Renal Disorders

Infectious Disease

Skin Disorders

Respiratory Disorders

Ocular Disorders

Antisense and RNAi therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa